Back to Journals » Medical Devices: Evidence and Research » Volume 4

Everolimus-eluting stents: update on current clinical studies

Authors Allocco D, Joshi A, Dawkins KD

Published 26 July 2011 Volume 2011:4 Pages 91—98

DOI https://doi.org/10.2147/MDER.S22043

Review by Single-blind

Peer reviewer comments 3


Video abstract presented by Dominic Allocco

Views: 2417

Dominic J Allocco, Anita A Joshi, Keith D Dawkins
Boston Scientific Corporation, Natick, MA, USA
Abstract: Everolimus-eluting stents (EES) have become the most commonly implanted coronary stents worldwide. This review describes and analyzes the clinical data supporting the use of EES, focusing primarily on published, randomized, controlled trials. Everolimuseluting stents have been shown to have less restenosis, stent thrombosis, and periprocedural myocardial infarction compared with earlier generation paclitaxel-eluting stents (PES). Lower rates of adverse events for EES compared with PES were generally seen in all subgroups, with the notable exception of patients with diabetes mellitus. There have been fewer, randomized, clinical trials comparing EES with either sirolimus-eluting stents or zotarolimus-eluting stents, although very good results with EES have been observed in the trials that have been performed. Recent clinical trial data suggest that this excellent safety and efficacy profile is maintained in a next-generation EES designed to have improved mechanical properties and radiopacity.

Keywords: drug-eluting stents, everolimus, Xience V, Promus, Promus Element

Video Abstract:  http://dvpr.es/allocco  

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]